Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus rating of “Hold” from the twenty-one research firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $106.10.

Several analysts recently commented on ZBH shares. Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday, November 5th. Barclays reduced their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently modified their holdings of ZBH. Key Financial Inc grew its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. grew its stake in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC increased its position in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares in the last quarter. Root Financial Partners LLC acquired a new position in Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet in the fourth quarter worth approximately $32,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $89.96 on Monday. The stock has a market cap of $17.83 billion, a price-to-earnings ratio of 22.27, a P/E/G ratio of 2.29 and a beta of 0.62. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. Zimmer Biomet has a twelve month low of $84.59 and a twelve month high of $114.44. The company’s fifty day moving average is $90.12 and its 200 day moving average is $95.73.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is 23.76%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.